# Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy

> **NIH NIH K23** · MASSACHUSETTS GENERAL HOSPITAL · 2022 · $54,000

## Abstract

Project Abstract:
The funded research project will advance our understanding of immunologic risk factors for infections, morbidity,
and mortality after chimeric antigen receptor (CAR) T-cell therapy. This research proposal utilizes a large
retrospective cohort of patients to determine the immunologic impact and clinical significance of
hypogammaglobulinemia following CAR T-cell therapy. Regression models and network analysis will be used to
define risk factors for development of infections and poor outcomes and to develop a clinical risk prediction
model. In accomplishing these aims, Dr. Barmettler will address critical gaps in our knowledge of immune
dysregulation following the use of CAR T-cell therapy with the ultimate goal of improving patient outcomes.
Dr. Barmettler will perform this work under the mentorship of Professor Carlos Camargo, an internationally
recognized expert in clinical epidemiology with an outstanding track record of mentorship. Dr. Barmettler has
assembled a team of mentors and collaborators with expertise in epidemiology, biostatistics, B-cell immunology,
CAR T-cell therapy, and infectious disease, whose support will contribute to the success of this project. Dr.
Barmettler is an Instructor in Medicine at Harvard Medical School (HMS) and Assistant in Medicine in Allergy-
Immunology at Massachusetts General Hospital (MGH) who has demonstrated academic productivity and a
strong commitment to clinical research. Her prior training and research in immune deficiency and investigating
immunologic outcomes in other B-cell targeted therapies (including the largest cohort to date of rituximab-treated
patients), have established the skills and experience critical for achieving her proposed research aims.
The research aims outlined in this proposal, along with collaborative opportunities and research environment at
MGH and HMS, will allow Dr. Barmettler to achieve the research and educational aims and to, thereby, establish
herself as an independent physician-scientist with expertise in advanced biostatistical techniques and
mechanisms of immune deficiency.

## Key facts

- **NIH application ID:** 10487663
- **Project number:** 3K23AI163350-02S1
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Sara Barmettler
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $54,000
- **Award type:** 3
- **Project period:** 2021-06-24 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10487663

## Citation

> US National Institutes of Health, RePORTER application 10487663, Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy (3K23AI163350-02S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10487663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*